Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 14, Issue 3, 2011, Pages 211-218

  Zhang, Jun ^a   Qi, Juan ^a   Guo, Yan ^a   Guo, Yi ^a   Fu, Weineng ^a   Zhou, Baosen ^a   Wu, Guangping ^a   Han, Libo ^a   He, Anguang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Hepatoma derived growth factor; Lung neoplasms; Prognosis; Survival analysis

Indexed keywords

BIOLOGICAL MARKER; HEPATOMA DERIVED GROWTH FACTOR;

ARTICLE; CANCER SURGERY; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 79953165398     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.03.06     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010. CA Cancer J Clin, 2010, 60(5): 277-300.
2. Chen WQ, Zhang SW, Zou XN. Estimation and projection of lung cancer incidence and mortality in China. Chin J Lung Cancer, 2010, 13(5): 488-493. (Chinese source 2010, 13(5): 488-493)
3. Silvestri GA, Alberg AJ, Ravenel J. The changing epidemiology of lung cancer with a focus on screening. BMJ, 2009, 339: b3053.
4. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008, 83(5): 584-594.
5. Enomoto H, Yoshida K, Kishima Y, et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology, 2002, 36(6): 1519-1527.
6. Everett AD, Narron JV, Stoops T, et al. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol, 2004, 286(6): L1194-1201.
7. Everett AD, Lobe DR, Matsumura ME, et al. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest, 2000, 105(5): 567-575.
8. Okuda Y, Nakamura H, Yoshida K, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo though both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci, 2003, 94(12): 1034-1041.
9. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression level of hepatoma- derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol, 2007, 14(7): 2141-2149.
10. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res, 2006, 12(1): 117-122.
11. Mao J, Xu Z, Fang Y, et al. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci, 2008, 99(11): 2120-2127.
12. Zhou Y, Zhou N, Fang W, et al. Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol, 2010, 5: 58.
13. Liu YF, Zhao R, Guo S, et al. Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann Surg Oncol, 2011, 18(3): 872-879.
14. Uyama H, Tomita Y, Nakamura H, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res, 2006, 12(20): 6043-6048.
15. Zhang J, Ren H, Yuan P, et al. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res, 2006, 66(1): 18-23.
16. Ren H, Tang X, Lee JJ, et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol, 2004, 22(16): 3230-3237.
17. Iwasaki T, Nakaqawa K, Nakamura H, et al. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep, 2005, 13(6): 1075-1080.
18. Zhang J, Mao L. SiRNA targeting hepatoma-derived growth factor (HDGF) inhibits growth of non-small cell lung cancer in xenograft models. Umor Biology 35: Emerging Molecules, Mechanisms, and Models. Proc Am Assoc Cancer Res, 2006, 47: Abstract 5135.
19. Wimmel A, Glitz D, Kraus A, et al. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer, 2001, 37(17): 2264-2274.
20. Shintani Y, Higashiyama S, Ohta M, et al. Overexpression of ADAM9 in non- small cell lung cancer correlates with brain metastasis. Cancer Res, 2004, 64(12): 4190-4196.
21. Qi J, Zhang J. Abnormal expression of ADAM9 in non-small cell lung cancers. J Chin Med Univ, 2010, 39(8): 670-671.(Chinese source 2010, 39(8): 670-671)
22. Mountain CF. Revisions in the international system for staging lung cancer. Chest, 1997, 111(6): 1710-1717.
23. Li Y, Li HY, Hu YX, et al, Clinical study of lymph node metastasis in lung cancer. Chin J Thorac Cardiovasc Surg, 2000, 16(1): 10-12. (Chinese source 2000, 16(1): 10-12)
24. Defranchi SA, Cassivi SD, Nichols FC, et al. N2 disease in T1 non-small cell lung cancer. Ann Thorac Surg, 2009, 88(3): 924-928.
25. Nameki N, Tochio N, Koshiba S, et al. Solution structure of the PWWP domain of the hepatoma-derived growth factor family. Protein Sci, 2005, 14(3): 756-764.
26. Yang J, Everett AD. Hepatoma derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol, 2007, 8: 101.
27. Yang J, Everett AD. Hepatoma-derived growth factor represses SET and MYND domain containing 1 gene expression through interaction with C-terminal binding protein. J Mol Biol, 2009, 386(4): 938-950.
28. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther, 2009, 8(5): 1106-1112.
29. Meng J, Xie W, Cao L, et al. shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim Biophys Sin, 2010, 42(1): 52-57.
30. Detterbeck FC, Tanoue LT, Boffa DJ. Anatomy, biology and concepts, pertaining to lung cancer stage classification. J Thorac Oncol, 2009, 4(4): 437-443.
31. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest, 2009, 136(1): 260-271.
32. Douillard JY. Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. J Clin Oncol, 2010, 28(1): 3-5.
33. Zhu CQ, Ding K, Strumpf F, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol, 2010, 28(29): 4417-4424.
34. Xie Y, Minna JD. Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. J Clin Oncol, 2010, 28(29): 4404-4407.